Blog

Cambridge biotech discloses it quietly reduced staff by 28% last year

foghorn-therapeutics-ground-breaking900xx3600-2408-0-0

Karin Hellsvik, Foghorn’s vice president of corporate affairs and investor relations, said the decision was due to "macroeconomic challenges."

Read More